|
86 Companies |
|
137 Products |
|
137 Products |
|
85 Mechanisms of Action |
|
4 Trials |
|
2019 News |
|
| «12...89101112131415161718...3940» |
- Enrollment closed: Cognitive Behavior Therapy and Work Outcome (clinicaltrials.gov) - Mar 25, 2015
P=N/A, N=120, Active, not recruiting, Sponsor: Department of Veterans Affairs
Recruiting --> Active, not recruiting
- Trial completion: Feedback and Psychotherapeutic Competencies (clinicaltrials.gov) - Mar 20, 2015
P=N/A, N=20, Completed, Sponsor: Goethe University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Trial completion: Smoking Cessation for Veterans With Severe and Persistent Mental Illness (clinicaltrials.gov) - Mar 20, 2015
P2/3, N=179, Completed, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Phase classification: Fingolimod in Schizophrenia Patients (clinicaltrials.gov) - Mar 17, 2015
P2, N=40, Recruiting, Sponsor: Indiana University
Active, not recruiting --> Completed Phase classification: P1 --> P2
- ||| olanzapine / Generic mfg.
Trial completion: eVAluatIon of OLanzapine TreatmEnT (clinicaltrials.gov) - Mar 17, 2015
P=N/A, N=468, Completed, Sponsor: Elpen Pharmaceutical Co. Inc.
Phase classification: P1 --> P2 Recruiting --> Completed
- Trial completion, Enrollment change: Reducing Weight and Diabetes Risk in an Underserved Population (STRIDE) (clinicaltrials.gov) - Mar 17, 2015
P2, N=200, Completed, Sponsor: Kaiser Permanente
Recruiting --> Completed Active, not recruiting --> Completed | N=280 --> 200
- Enrollment open: REACH: Researching the Effectiveness of Acceptance-Based Coping During Hospitalization (clinicaltrials.gov) - Mar 12, 2015
P=N/A, N=60, Recruiting, Sponsor: Butler Hospital
Active, not recruiting --> Completed | N=280 --> 200 Not yet recruiting --> Recruiting
- Aristada once-monthly (aripiprazole lauroxil once-monthly formulation) / Alkermes, Aristada two-month (aripiprazole lauroxil XR) / Alkermes
Enrollment open: An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia (clinicaltrials.gov) - Mar 11, 2015
P1, N=140, Recruiting, Sponsor: Alkermes, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial completion: Auditory Verbal Hallucinations in Schizophrenia (clinicaltrials.gov) - Mar 10, 2015
P=N/A, N=40, Completed, Sponsor: University Hospital, Grenoble
Not yet recruiting --> Recruiting Recruiting --> Completed
- Enrollment closed, Trial primary completion date: Treatment Development Targeting Severe and Persistent Negative Symptoms (clinicaltrials.gov) - Mar 7, 2015
P=N/A, N=50, Active, not recruiting, Sponsor: The University of Texas Health Science Center at San Antonio
Recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2014 --> Aug 2014
- | Lu AF11167 / Lundbeck
Trial completion: Pharmacokinetic Properties of Various Modified Release Tablet Formulations of Lu AF11167 (clinicaltrials.gov) - Mar 7, 2015
P1, N=28, Completed, Sponsor: H. Lundbeck A/S
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2014 --> Aug 2014 Recruiting --> Completed
- ||| Lu AF35700 / Lundbeck, Jiangsu NHWA Pharma
Trial completion: Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia (clinicaltrials.gov) - Mar 7, 2015
P1, N=96, Completed, Sponsor: H. Lundbeck A/S
Recruiting --> Completed Recruiting --> Completed
- Trial completion, Adherence: Improving Adherence to Oral Antipsychotic Medications in People With Schizophrenia (clinicaltrials.gov) - Mar 7, 2015
P=N/A, N=150, Completed, Sponsor: The University of Texas Health Science Center at San Antonio
Recruiting --> Completed Active, not recruiting --> Completed
- Rykindo (risperidone extended release microspheres) / Luye Group
Trial primary completion date: An Randomized Open-Label PK Study of LY03004 Compared to Risperdal (clinicaltrials.gov) - Mar 5, 2015
P1, N=16, Enrolling by invitation, Sponsor: Luye Pharma Group Ltd.
Active, not recruiting --> Completed Trial primary completion date: Nov 2014 --> May 2015
- | Enrollment closed, Trial primary completion date: CHANGE -it is About Life (clinicaltrials.gov) - Mar 5, 2015
P3, N=430, Active, not recruiting, Sponsor: Mental Health Services in the Capital Region, Denmark
Trial primary completion date: Nov 2014 --> May 2015 Not yet recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> May 2016
- ||| Rykindo (risperidone extended release microspheres) / Luye Group
Trial completion, Phase classification: Bioavailability of LY03004 and Risperdal (clinicaltrials.gov) - Mar 5, 2015
P1, N=108, Completed, Sponsor: Luye Pharma Group Ltd.
Not yet recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> May 2016 Recruiting --> Completed | Phase classification: P1/2 --> P1
- Trial completion: Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders (clinicaltrials.gov) - Mar 5, 2015
P0, N=68, Completed, Sponsor: New York State Psychiatric Institute
Recruiting --> Completed | Phase classification: P1/2 --> P1 Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: MCT: Metacognitive Training in Schizophrenia (clinicaltrials.gov) - Mar 3, 2015
P=N/A, N=60, Completed, Sponsor: Universit
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: May 2012 --> Dec 2013
- || pregabalin / Generic mfg.
Trial primary completion date: PACS: Pregablin for Anxiety-comorbidity in Patients With Schizophrenia (clinicaltrials.gov) - Feb 27, 2015
P4, N=70, Recruiting, Sponsor: University of Aarhus
Active, not recruiting --> Completed | Trial primary completion date: May 2012 --> Dec 2013 Trial primary completion date: Dec 2014 --> Feb 2016
- | Rexulti (brexpiprazole) / Lundbeck, Otsuka
Enrollment open, Monotherapy: Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity (clinicaltrials.gov) - Feb 27, 2015
P3, N=36, Recruiting, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Trial primary completion date: Dec 2014 --> Feb 2016 Not yet recruiting --> Recruiting
- Enrollment open, Trial primary completion date: Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia (clinicaltrials.gov) - Feb 24, 2015
P2, N=80, Recruiting, Sponsor: New York University School of Medicine
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2017 --> Dec 2017
- Enrollment closed, Enrollment change: Implementation of Illness Management and Recovery in Mental Health Services (clinicaltrials.gov) - Feb 24, 2015
P=N/A, N=40, Active, not recruiting, Sponsor: University Hospital, Akershus
Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2017 --> Dec 2017 Recruiting --> Active, not recruiting | N=130 --> 40
- roluperidone (MIN-101) / Mitsubishi Tanabe, Minerva Neurosciences
Trial completion: Pharmacokinetic Study of MIN-101 in Healthy Subjects (clinicaltrials.gov) - Feb 24, 2015
P1, N=32, Completed, Sponsor: Minerva Neurosciences
Recruiting --> Active, not recruiting | N=130 --> 40 Recruiting --> Completed
- JNJ-39393406 / J&J
Enrollment open: Novel Smoking Cessation Drug for Schizophrenia (clinicaltrials.gov) - Feb 20, 2015
P2, N=60, Recruiting, Sponsor: K.N. Roy Chengappa
Recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment open, Trial primary completion date: Effects of Systematic Patient Feedback on Therapy Outcome (clinicaltrials.gov) - Feb 20, 2015
P=N/A, N=120, Recruiting, Sponsor: Norwegian University of Science and Technology
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting | Trial primary completion date: Jun 2014 --> Jun 2016
- valacyclovir / Generic mfg.
Trial primary completion date: To Rescue Cognition With Valaciclovir (clinicaltrials.gov) - Feb 19, 2015
P2, N=24, Recruiting, Sponsor: University Medical Centre Groningen
Active, not recruiting --> Recruiting | Trial primary completion date: Jun 2014 --> Jun 2016 Trial primary completion date: Aug 2014 --> Aug 2015
- Trial primary completion date: Measuring Time Windows in Patients With Schizophrenia and Healthy Controls (clinicaltrials.gov) - Feb 19, 2015
P=N/A, N=228, Recruiting, Sponsor: University Hospital, Strasbourg, France
Trial primary completion date: Aug 2014 --> Aug 2015 Trial primary completion date: Dec 2014 --> Dec 2016
- lenrispodun (ITI-214) - Intra / Cellular Therapies
Trial termination: Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia (clinicaltrials.gov) - Feb 19, 2015
P1, N=76, Terminated, Sponsor: Takeda
Trial primary completion date: Dec 2014 --> Dec 2016 Recruiting --> Terminated; Business Decision; No Safety or Efficacy Concerns
- | Lu AF11167 / Lundbeck
Trial completion, Enrollment change: Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia (clinicaltrials.gov) - Feb 19, 2015
P1, N=47, Completed, Sponsor: H. Lundbeck A/S
Recruiting --> Terminated; Business Decision; No Safety or Efficacy Concerns Recruiting --> Completed | N=72 --> 47
- Trial completion: rTMS-induced Cumulative Pattern of sBDNF in Chronic Schizophrenia (clinicaltrials.gov) - Feb 19, 2015
P=N/A, N=21, Completed, Sponsor: Jeonbuk Provincial Maeumsarang Hospital
Recruiting --> Completed | N=72 --> 47 Recruiting --> Completed
- | Enrollment change, Trial primary completion date: The Topical Niacin Skin Flush Test in First Episode Psychosis (clinicaltrials.gov) - Feb 12, 2015
P3, N=100, Recruiting, Sponsor: Capital District Health Authority, Canada
Recruiting --> Completed N=200 --> 100 | Trial primary completion date: Dec 2014 --> Jun 2015
- Trial completion, Enrollment change: MEMENTA: Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder (clinicaltrials.gov) - Feb 11, 2015
P=N/A, N=371, Completed, Sponsor: Technische Universit
N=200 --> 100 | Trial primary completion date: Dec 2014 --> Jun 2015 Recruiting --> Completed | N=600 --> 371
- | Enrollment closed: Shared Decision Making for Patients With First-admission Schizophrenia (clinicaltrials.gov) - Feb 10, 2015
P2/3, N=52, Active, not recruiting, Sponsor: Yokohama City University
Recruiting --> Completed | N=600 --> 371 Recruiting --> Active, not recruiting
- Enrollment closed, Trial primary completion date: Oxytocin as Adjunctive Therapy for Schizophrenia (clinicaltrials.gov) - Feb 10, 2015
P2, N=80, Active, not recruiting, Sponsor: IRCCS Centro San Giovanni di Dio Fatebenefratelli
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jun 2015
- minocycline / Generic mfg., clozapine / Generic mfg.
Enrollment open: Minocycline Augmentation to Clozapine (clinicaltrials.gov) - Feb 9, 2015
P4, N=35, Recruiting, Sponsor: Emory University
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jun 2015 Not yet recruiting --> Recruiting
- | ulotaront (SEP-363856) / Otsuka, PsychoGenics
Trial completion: Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia (clinicaltrials.gov) - Feb 9, 2015
P1, N=48, Completed, Sponsor: Sunovion
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
Trial completion: Brexpiprazole in Patients With Acute Schizophrenia (clinicaltrials.gov) - Feb 6, 2015
P3, N=465, Completed, Sponsor: H. Lundbeck A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial primary completion date: Effects of rTMS on Cigarette Smoking and Cognition in Schizophrenia (clinicaltrials.gov) - Feb 5, 2015
P=N/A, N=50, Recruiting, Sponsor: Centre for Addiction and Mental Health
Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> Sep 2015
- Phase classification: Cerebellar rTMS for the Treatment of Schizophrenic Patients (clinicaltrials.gov) - Feb 5, 2015
P=N/A, N=20, Completed, Sponsor: Beth Israel Deaconess Medical Center
Trial primary completion date: Dec 2014 --> Sep 2015 Phase classification: P1 --> P=N/A
- quetiapine / Generic mfg.
Enrollment open: The Influence of Vitamin D on Atypical Antipsychotic-induced Weight Gain (clinicaltrials.gov) - Feb 5, 2015
P=N/A, N=40, Recruiting, Sponsor: Creighton University
Phase classification: P1 --> P=N/A Not yet recruiting --> Recruiting
- |||||| Perseris (risperidone sustained-release 1-month depot) / Indivior, Reckitt Benckiser, HLS Therap
Clinical: Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia (clinicaltrials.gov) - Feb 5, 2015
P3, N=500, Recruiting, Sponsor: Reckitt Benckiser Pharmaceuticals Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- ||||||| Perseris (risperidone sustained-release 1-month depot) / Indivior, Reckitt Benckiser, HLS Therap
Clinical: Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients (clinicaltrials.gov) - Feb 5, 2015
P3, N=259, Completed, Sponsor: Reckitt Benckiser Pharmaceuticals Inc.
Active, not recruiting --> Recruiting Recruiting --> Completed | N=339 --> 259 | Trial primary completion date: Mar 2015 --> Dec 2014
- Trial completion, Trial initiation date: Clinical Estradiol Trial in Women With Schizophrenia (clinicaltrials.gov) - Feb 5, 2015
P2, N=100, Completed, Sponsor: Bayside Health
Recruiting --> Completed | N=339 --> 259 | Trial primary completion date: Mar 2015 --> Dec 2014 Recruiting --> Completed | Initiation date: Jan 2002 --> Jan 2001
- Chantix (varenicline) / Pfizer
Trial primary completion date: Effect of Varenicline on Cognitive Function in Cigarette Smokers With Schizophrenia (clinicaltrials.gov) - Feb 3, 2015
P=N/A, N=40, Recruiting, Sponsor: Centre for Addiction and Mental Health
Recruiting --> Completed | Initiation date: Jan 2002 --> Jan 2001 Trial primary completion date: Dec 2014 --> Aug 2016
- Trial initiation date: Transcranial Direct Current Stimulation Influences on Cognitive Inhibition in Schizophrenia (clinicaltrials.gov) - Feb 3, 2015
P=N/A, N=30, Not yet recruiting, Sponsor: Bar-Ilan University, Israel
Trial primary completion date: Dec 2014 --> Aug 2016 Initiation date: Jul 2014 --> Jan 2015
- || Arvisol (cannabidiol CR) / Echo Pharma
Trial primary completion date: CBD-IS: Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study (clinicaltrials.gov) - Feb 2, 2015
P1, N=74, Recruiting, Sponsor: Central Institute of Mental Health, Mannheim
Initiation date: Jul 2014 --> Jan 2015 Trial primary completion date: Jun 2014 --> Jun 2015
- ||| l-methylfolate / Generic mfg.
Trial completion: A Placebo-Controlled Study of Physiologic Effects of L-methylfolate in Schizophrenia Patients (clinicaltrials.gov) - Feb 2, 2015
P=N/A, N=55, Completed, Sponsor: Pamlab, Inc.
Trial primary completion date: Jun 2014 --> Jun 2015 Active, not recruiting --> Completed
- Enrollment closed, Trial primary completion date: Remediation of Working Memory in Schizophrenia (clinicaltrials.gov) - Jan 30, 2015
P=N/A, N=80, Active, not recruiting, Sponsor: Minneapolis Veterans Affairs Medical Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Apr 2015
- raloxifene hydrochloride / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: SERM: Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia (clinicaltrials.gov) - Jan 30, 2015
P4, N=54, Completed, Sponsor: The Alfred
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Apr 2015 Recruiting --> Completed | N=90 --> 54 | Trial primary completion date: Dec 2015 --> Dec 2014
- | aripiprazole / Generic mfg.
Enrollment change, Trial primary completion date: ATTAIN 267: Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features. (clinicaltrials.gov) - Jan 29, 2015
P3, N=511, Terminated, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting --> Completed | N=90 --> 54 | Trial primary completion date: Dec 2015 --> Dec 2014 N=651 --> 511 | Trial primary completion date: Dec 2014 --> Aug 2014